ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

DANIEL NOVAK M.D.

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,083Medicare Part D Prescriptions Filled, Including Refills

Rank: 528 out of 2888

$155K Total Retail Price of All Prescriptions

Rank: 2124 out of 2888

446 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
98% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

19% of this provider’s 446 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

0% of this provider’s 8,074 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$15 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
LISINOPRIL 818 648 1 3
SIMVASTATIN 540 462 2 2
HYDROCODONE-ACETAMINOPHEN 463 408 S3 3 4
FUROSEMIDE 452 398 4 6
WARFARIN SODIUM 359 308 5 22
LEVOTHYROXINE SODIUM 291 221 6 1
GABAPENTIN 282 181 7 13
SERTRALINE HCL 228 208 8 27
POTASSIUM CHLORIDE 206 187 9 14
ATORVASTATIN CALCIUM 202 139 10 9
AMLODIPINE BESYLATE 198 170 11 5
HYDROCHLOROTHIAZIDE 187 133 12 15
ATENOLOL 183 131 13 25
METOPROLOL TARTRATE 183 153 13 10
FELODIPINE ER 157 106 15 175
OMEPRAZOLE 147 106 16 7
CITALOPRAM HBR 143 125 17 24
METOPROLOL SUCCINATE 134 119 18 11
PANTOPRAZOLE SODIUM 128 109 19 33
LOSARTAN POTASSIUM 127 112 20 18
NEXIUM 111 79 21 19
LANTUS SOLOSTAR 111 97 21 92
CARVEDILOL 107 93 23 21
NOVOLIN 70-30 103 75 24 144
TRAZODONE HCL 97 85 25 43
METFORMIN HCL 96 59 26 8
CLOPIDOGREL 91 84 27 30
PLAVIX 91 74 27 40
LANTUS 87 45 29 45
NAMENDA 78 78 30 34
ESCITALOPRAM OXALATE 75 75 31 62
GLIPIZIDE 73 62 32 50
ALLOPURINOL 73 55 32 37
METOLAZONE 72 62 34 215
ZOLPIDEM TARTRATE 69 65 35 17
CLONIDINE HCL 69 56 35 39
RANITIDINE HCL 67 49 37 56
QUETIAPINE FUMARATE 66 57 38 66
CYMBALTA 66 43 38 44
ALENDRONATE SODIUM 61 48 40 23
METFORMIN HCL ER 59 34 41 53
VENTOLIN HFA 59 38 41 173
DONEPEZIL HCL 59 57 41 26
KLOR-CON 10 57 38 44 195
DIGOXIN 53 53 45 55
ADVAIR DISKUS 53 35 45 60
DIVALPROEX SODIUM 51 41 47 100
GEMFIBROZIL 51 26 47 98
NOVOLOG 50 18 49 114
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 12, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.